Search Results - "MUKAIYAMA, Akihira"

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN— A Randomized, Phase III Study by SATOH, Taroh, XU, Rui-Hua, MIWA, Hiroto, QIN, Shu-Kui, CHUNG, Ik-Joo, YEH, Kun-Huei, FENG, Ji-Feng, MUKAIYAMA, Akihira, KOBAYASHI, Mikiro, OHTSU, Atsushi, BANG, Yung-Jue, HYUN CHEOL CHUNG, SUN, Guo-Ping, DOI, Toshihiko, XU, Jian-Ming, TSUJI, Akihito, OMURO, Yasushi, JIN LI, WANG, Jin-Wan

“…In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2…”
Get full text

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma by Yamazaki, Naoya, Tsutsumida, Arata, Takahashi, Akira, Namikawa, Kenjiro, Yoshikawa, Shusuke, Fujiwara, Yutaka, Kondo, Shunsuke, Mukaiyama, Akihira, Zhang, Fanghong, Kiyohara, Yoshio

“…The combination of dabrafenib and trametinib demonstrated encouraging antitumor activity and tolerability, at initial analysis, in Japanese patients with BRAF…”
Get full text

Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors by Nakagawa, Kazuhiko, Minami, Hironobu, Kanezaki, Masayuki, Mukaiyama, Akihira, Minamide, Yoshiyuki, Uejima, Hisao, Kurata, Takayasu, Nogami, Toshiji, Kawada, Kenji, Mukai, Hirofumi, Sasaki, Yasutsuna, Fukuoka, Masahiro

“…Objective The Phase I dose-escalation study was conducted to evaluate the safety and pharmacokinetics of lapatinib (GW572016), a dual ErbB-1 and -2 inhibitor,…”
Get full text

10152-PEDT-5 JAPANESE SUBGROUP ANALYSIS OF A PHASE II TRIAL OF DABRAFENIB PLUS TRAMETINIB (D+T) IN BRAF V600-MUTANT PEDIATRIC LOW-GRADE GLIOMA (PLGG) AND RELAPSED/REFRACTORY (R/R) BRAF V600-MUTANT PEDIATRIC HIGH-GRADE GLIOMA (PHGG) by Terashima, Keita, Koga, Yuhki, Mukaiyama, Akihira, Kurihara, Ryohei, Okada, Keiko

“…Abstract BACKGROUND pLGG is the most common pediatric brain cancer, and BRAF V600 mutation has been detected in ≈17% of cases. pHGGs comprise ≈10% of pediatric…”
Get full text

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study by Fujiwara, Yutaka, Yamazaki, Naoya, Kiyohara, Yoshio, Yoshikawa, Shusuke, Yamamoto, Noboru, Tsutsumida, Arata, Nokihara, Hiroshi, Namikawa, Kenjiro, Mukaiyama, Akihira, Zhang, Fanghong, Tamura, Tomohide

“…Background Dabrafenib is a BRAF inhibitor that has demonstrated clinical activity with a good tolerability profile in patients with BRAF mutated metastatic…”
Get full text

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAFV600 mutation-positive solid tumors: a phase 1 study by Fujiwara, Yutaka, Yamazaki, Naoya, Kiyohara, Yoshio, Yoshikawa, Shusuke, Yamamoto, Noboru, Tsutsumida, Arata, Nokihara, Hiroshi, Namikawa, Kenjiro, Mukaiyama, Akihira, Zhang, Fanghong, Tamura, Tomohide

“…Summary Background Dabrafenib is a BRAF inhibitor that has demonstrated clinical activity with a good tolerability profile in patients with BRAF V600E mutated…”
Get full text

A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors by Kasuga, Akiyoshi, Nakagawa, Kazuhiko, Nagashima, Fumio, Shimizu, Toshio, Naruge, Daisuke, Nishina, Shinichi, Kitamura, Hiroshi, Kurata, Takayasu, Takasu, Atsuko, Fujisaka, Yasuhito, Okamoto, Wataru, Nishimura, Yuichiro, Mukaiyama, Akihira, Matsushita, Hideki, Furuse, Junji

“…Summary Background Trametinib is an inhibitor of MEK1/MEK2 activation and kinase activity. In order to evaluate the safety, tolerability, pharmacokinetics, and…”
Get full text

A phase I/I b study of GSK1120212 (trametinib) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors by Kurata, Takayasu, Furuse, Junji, Okamoto, Isamu, Kasuga, Akiyoshi, Fujisaka, Yasuhito, Kitamura, Hiroshi, Shimizu, Toshio, Takasu, Atsuko, Okamoto, Wataru, Naruge, Daisuke, Nagashima, Fumio, Katsura, Koichi, Mukaiyama, Akihira, Matsushita, Hideki, Nakagawa, Kazuhiko

“…Abstract only e20004 Background: Trametinib is a potent and selective allosteric MEK1/2 inhibitor. In Western countries, trametinib was investigated as…”
Get full text

Degradation of Interleukin 1β by Matrix Metalloproteinases by Ito, Akira, Mukaiyama, Akihira, Itoh, Yoshifumi, Nagase, Hideaki, Thøgersen, Ida B., Enghild, Jan J., Sasaguri, Yasuyuki, Mori, Yo

“…Matrix metalloproteinases (MMPs) and interleukin 1 (IL-1) are implicated in inflammation and tissue destruction, where IL-1 is a potent stimulator of…”
Get full text

Phase I and Pharmacologic Study of Weekly Bolus Topotecan for Advanced Non–Small-Cell Lung Cancer by Masuda, Noriyuki, Matsui, Kaoru, Negoro, Shunichi, Takeda, Koji, Kudoh, Shinzoh, Nakagawa, Kazuhiko, Mukaiyama, Akihira, Arase, Hiroaki, Yoshida, Pascal, Ijima, Toshiyuki, Takada, Minoru, Fukuoka, Masahiro

“…Abstract Purpose We conducted a phase I trial of the topoisomerase I inhibitor topotecan for the purpose of determining the maximum tolerated dose (MTD) and…”
Get full text

Degradation of Interleukin 1β by Matrix Metalloproteinases by Akira Ito, Akihira Mukaiyama, Yoshifumi Itoh, Hideaki Nagase, Ida B. Thøgersen, Jan J. Enghild, Yasuyuki Sasaguri, Yo Mori

“…Matrix metalloproteinases (MMPs) and interleukin 1 (IL-1) are implicated in inflammation and tissue destruction, where IL-1 is a potent stimulator of…”
Get full text